A phase I dose-escalation study of enzalutamide in combination with the AKT inhibitor AZD5363 (capivasertib) in patients with metastatic castration-resistant prostate cancer

Michael Kolinsky, Pasquale Rescigno, Diletta Bianchini, Zafeiris Zafeiriou, Niven Mehra, Joaquı́n Mateo, Vasiliki Michalarea, Ruth Riisnaes, Mateus Crespo, I. Figueiredo, Susana Miranda, Daniel Nava Rodrigues, Penelope Flohr, Nina Tunariu, Udai Banerji, Ruth Ruddle, Adam Sharp, Jonathan Welti, Maryou Lambros, Suzanne Carreira, Florence I. Raynaud, Karen E. Swales, Stephen R. Plymate, Jun Luo, Holly Tovey, Núria Porta, Rachel M. Slade, Lorna Leonard, Emma Hall, Johann S. de Bono